# ARBLI (losartan) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/losartan

> The FDA approved ARBLI (losartan), sponsored by Scienture Holdings, Inc. (SCNX), on March 13, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ARBLI (losartan) |
| Codes | SCN-102 |
| Sponsor | Scienture Holdings, Inc. (SCNX) https://sec-api.dev/companies/scnx/catalysts |
| Indications |  |
| Modality | small_molecule |
| FDA designations | none disclosed |

## Timeline

### August 19, 2024: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22218772_2025_Orig1s000OtherActionLtrs.pdf%22

### March 13, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-21, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218772 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250313, review_priority STANDARD; sponsor_name SCIENTURE; product ARBLI (LOSARTAN POTASSIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218772%22
- Press release filed with the SEC (EX-99) (accession 0001493152-25-011152): "FL, March 18, 2025 (GLOBE NEWSWIRE) — - SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc., with the brand name ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL." https://www.sec.gov/Archives/edgar/data/1382574/000149315225011152/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-25-011152): "SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL." https://www.sec.gov/Archives/edgar/data/1382574/000149315225011152/ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/losartan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ARBLI (losartan) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/losartan

```bibtex
@misc{secapidev_pdufa_losartan_20261116,
  title        = {ARBLI (losartan) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/losartan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_losartan_20261116","title":"ARBLI (losartan) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/losartan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
